Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Kiyomi Mashima, Benjamin L. Lampson, Aditi Gupta, Nicholas Moore, Anna Petrackova, Samantha J. Shupe, Stacey M. Fernandes, Amaro Taylor-Weiner, Riaz Gillani, Hoyin Chu, Seunghun Han, Sabrina Camp, Eric Kofman, Gad Getz, Catherine J. Wu, Eliezer Van Allen, Saud H AlDubayan, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9853–9854.

https://doi.org/10.1182/blood-2022-167009

Published: 2022

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2021-147263

Published: 2021

Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139864

Published: 2020

Journal Articles

Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-135919

Published: 2020

Journal Articles

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-140965

Published: 2020

Journal Articles

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Sagar Koduri, MD PhD, Adam C. Wang, B.S., Mette Ishoey, PhD, Joshiawa Paulk, Xiaoxi Liu, PhD, Isaac Harris, PhD, Jennifer Endress, B.S., Benjamin L. Lampson, MD PhD, Christopher J. Ott, PhD, James Bradner, MD, Jeffrey A. Medin, PhD, Sara J Buhrlage, PhD, William Kaelin, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-141558

Published: 2020

Journal Articles

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Austin I Kim, MD, Reid W Merryman, MD, Jessica Lowney, Josie Montegaard, NP, Victoria Patterson, RN, Caron A. Jacobson, MD, Eric D Jacobsen, MD, Ann S. LaCasce, MD MMSc, Jon E. Arnason, MD, Philippe Armand, MD PhD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 32.

https://doi.org/10.1182/blood-2019-127506

Published: 2019

Journal Articles

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Conner J. Shaughnessy, Annette S. Kim, MD PhD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 1731.

https://doi.org/10.1182/blood-2019-127180

Published: 2019

Journal Articles

Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib

Alexander R. Vartanov, MD, Tiago R Matos, MD, Emily M. McWilliams, PhD, Deepti Gadi, PhD, Deepak Rao, MD PhD, Siddha Kasar, PhD, Benjamin L. Lampson, MD PhD, Stacey M. Fernandes, BS, Jerome Ritz, MD PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2018-99-118734

Published: 2018

Journal Articles

A new triple threat to CLL

Benjamin L. Lampson, Matthew S. Davids

Blood (2018) 132 (15): 1547–1548.

https://doi.org/10.1182/blood-2018-08-870808

Published: 2018

Journal Articles

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Benjamin L. Lampson, MD PhD, Haesook T Kim, PhD, Matthew S. Davids, MD, Jeremy S. Abramson, MD MMSc, Arnold S. Freedman, MD, Caron A. Jacobson, MD, Philippe Armand, MD PhD, Robin M. Joyce, MD, Jon E. Arnason, MD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, Samantha Huang, Joshua Fein, John Hanna, Stacey Marie Fernandes, BS, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 1734.

https://doi.org/10.1182/blood.V130.Suppl_1.1734.1734

Published: 2017

Journal Articles

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi, Jennifer R. Brown

Blood (2017) 129 (18): 2581–2584.

https://doi.org/10.1182/blood-2016-10-742437

Published: 2017

Includes: Supplemental data

Journal Articles

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Benjamin L. Lampson, Siddha N. Kasar, Tiago R. Matos, Elizabeth A. Morgan, Laura Rassenti, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Caron A. Jacobson, Philippe Armand, Jeremy S. Abramson, Jon E. Arnason, Thomas J. Kipps, Joshua Fein, Stacey Fernandes, John Hanna, Jerome Ritz, Haesook T. Kim, Jennifer R. Brown

Blood (2016) 128 (2): 195–203.

https://doi.org/10.1182/blood-2016-03-707133

Published: 2016

Includes: Supplemental data

Journal Articles

Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities

Benjamin L Lampson, MD PhD, Tiago Matos, MD MSc, Haesook T. Kim, PhD, Siddha Kasar, PhD, Elizabeth A. Morgan, MD, Masahiro Hirakawa, MD PhD, Joshua Fein, Stacey M. Fernandes, Jerome Ritz, MD, Jennifer R. Brown, MD PhD

Blood (2015) 126 (23): 497.

https://doi.org/10.1182/blood.V126.23.497.497

Published: 2015

Journal Articles

Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib

Tiago R Matos, MD MSc, Benjamin L Lampson, MD PhD, Masahiro Hirakawa, MD PhD, Siddha Kasar, PhD, Stacey M. Fernandes, Jennifer R. Brown, MD PhD, Jerome Ritz, MD

Blood (2015) 126 (23): 1735.

https://doi.org/10.1182/blood.V126.23.1735.1735

Published: 2015

NARROW

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib

A new triple threat to CLL

Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities

Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only